Search
Conteltinib
go.drugbank.com/drugs/DB21262InvestigationalConteltinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Conteltinib is a tyrosine kinase inhibitor. … Conteltinib is under investigation in clinical trial NCT06970132 (Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation).
Osunprotafib
go.drugbank.com/drugs/DB21547InvestigationalOsunprotafib is a small molecule drug. The usage of the INN stem '-protafib' in the name indicates that Osunprotafib is a human protein tyrosine phosphatase (HPTP) inhibitor. … Osunprotafib is under investigation in clinical trial NCT04777994 (Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors).
Zoracopan
go.drugbank.com/drugs/DB21702InvestigationalZoracopan is a small molecule drug. The usage of the INN stem '-copan' in the name indicates that Zoracopan is a complement receptor antagonist/complement inhibitor. … Zoracopan is under investigation in clinical trial NCT06173596 (A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults).
Arsthinol
go.drugbank.com/drugs/DB08928ExperimentalArsthinol (INN) is an antiprotozoal agent that was first synthesized by Ernst A.H. Friedheim in 1949 via the complexing of acetarsol with 2,3-dimercaptopropanol. … Considered well tolerated when compared to other related trivalent organoarsenicals, arsthinol has even undergone recent studies as a potential anticancer agent.
Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15683ApprovedInvestigationalBifeprunox
go.drugbank.com/drugs/DB04888InvestigationalBifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
Otilimab
go.drugbank.com/drugs/DB06303InvestigationalInvestigated for the treatment of osteoarthritis and rheumatoid arthritis (RA).
Abexinostat
go.drugbank.com/drugs/DB12565InvestigationalAbexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. … It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.